Progenics Pharmaceuticals (PGNX) Posts Narrower than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported Q3 loss of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $6.5 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
